

REMARKS

The examiner alleges that this application fails to comply with one or more of the requirements of 37 C.F.R. §1.182 through 1.825 with respect to the sequence disclosures at pages 95-97 (SEQ ID NO: 753, SEQ ID NO: 968, SEQ ID NO: 2936, SEQ ID NO: 1690 and SEQ ID NO: 2603). Applicants respectfully submit that it is not necessary to submit a substitute sequence listing for the sequences located on pages 95-97 of the specification. MPEP § 2422.03 states that “[i]n those instances in which prior art sequences are only referred to in a given application by name and a publication or accession reference, they need not be included as part of the ‘Sequence Listing,’ unless an examiner considers the referred-to sequence to be ‘essential material’ per MPEP §608.01(p).” The aforementioned sequences cited on pages 95-97 of the specification are blast sequences and are given in Example 1 as examples of homologous sequences. The actual string of amino acids or bases is not given nor does the examiner allege that the sequences are essential material. Therefore, applicants respectfully submit that it is not necessary to include the blast sequences on pages 95-97 of the specification in the Sequence Listing. Should the examiner have any questions in this regard, he is invited to contact the undersigned at 215.568.3100.

Respectfully submitted,

Date: November 2, 2009

/Felicity E. Groth/
Felicity E. Groth
Registration No. 47,042

Woodcock Washburn LLP
Cira Centre, 12th Floor
2929 Arch Street
Philadelphia, PA 19104-2891
Telephone: (215) 568-3100
Facsimile: (215) 568-3439